期刊文献+

Activity of T Cells Stimulated by Hemagglutinin-neuraminidase of Newcastle Disease Virus in vivo 被引量:3

Activity of T Cells Stimulated by Hemagglutinin-neuraminidase of Newcastle Disease Virus in vivo
下载PDF
导出
摘要 To investigate the stimulated activity of T cells and the anti-tumor properties of hemagglutinin-neuraminidase(HN) of Newcastle disease virus(NDV) strain Changchun(NDVcc), the expression of HN gene in hepatoma cells(human HepG-2 and mouse H22 cells) infected with the recombinant adenovirus(Ad-HN) was identified by Western blot analysis and flow cytometry. Sialidase activity of NDVcc HN expressed by Ad-HN was assayed by the periodate-resorcinol method. The in vivo anti-tumor effects of NDVcc HN were evaluated in the H22 solid tumor model. Regional lymph nodes of the mouse model treated with Ad-HN were removed to harvest T lymphocytes and evaluating the specific cytotoxicity of cytotoxic T lymphocyte(CTL) and natural killer(NK) cells by an L-lactate dehydrogenase(LDH) assay, in the mean time, the secretion of cytokines was analyzed by enzyme linked immunosorbent assays(ELISA). The results show that NDVcc HN was effectively expressed by Ad-HN in HepG-2 and H22 cells. The sialidase activity assay showed that Ad-HN significantly reduced sialic acid level of the hepatoma cells compared with the cells infected the empty adenovirus vector(Ad-mock). When treated with Ad-HN, the growth of subcutaneous H22 primary tumors in C57BL/6 mice was suppressed, and the mean mice survival increased. In addition, the treatment of Ad-HN elicited strong NK and CTL responses, and high levels of Th1 cytokines, such as IL-2 and IFN-γ. In conclusion, NDVcc HN effectively elicits T cell-mediate anti-tumor cytotoxicity via sialidase activity and may be a novel strategy for cancer immunotherapy. To investigate the stimulated activity of T cells and the anti-tumor properties of hemagglutinin-neuraminidase(HN) of Newcastle disease virus(NDV) strain Changchun(NDVcc), the expression of HN gene in hepatoma cells(human HepG-2 and mouse H22 cells) infected with the recombinant adenovirus(Ad-HN) was identified by Western blot analysis and flow cytometry. Sialidase activity of NDVcc HN expressed by Ad-HN was assayed by the periodate-resorcinol method. The in vivo anti-tumor effects of NDVcc HN were evaluated in the H22 solid tumor model. Regional lymph nodes of the mouse model treated with Ad-HN were removed to harvest T lymphocytes and evaluating the specific cytotoxicity of cytotoxic T lymphocyte(CTL) and natural killer(NK) cells by an L-lactate dehydrogenase(LDH) assay, in the mean time, the secretion of cytokines was analyzed by enzyme linked immunosorbent assays(ELISA). The results show that NDVcc HN was effectively expressed by Ad-HN in HepG-2 and H22 cells. The sialidase activity assay showed that Ad-HN significantly reduced sialic acid level of the hepatoma cells compared with the cells infected the empty adenovirus vector(Ad-mock). When treated with Ad-HN, the growth of subcutaneous H22 primary tumors in C57BL/6 mice was suppressed, and the mean mice survival increased. In addition, the treatment of Ad-HN elicited strong NK and CTL responses, and high levels of Th1 cytokines, such as IL-2 and IFN-γ. In conclusion, NDVcc HN effectively elicits T cell-mediate anti-tumor cytotoxicity via sialidase activity and may be a novel strategy for cancer immunotherapy.
出处 《Chemical Research in Chinese Universities》 SCIE CAS CSCD 2011年第3期455-460,共6页 高等学校化学研究(英文版)
基金 Supported by the Genetically Modified Organisms Breeding Major Project of China(No.2009ZX08006-002B) the Key Technologies Research and Development Programme of Jilin Province, China(No.10ZDGG007)
关键词 Newcastle disease virus HEMAGGLUTININ-NEURAMINIDASE HEPATOMA T Cell Anti-tumor immunity Newcastle disease virus Hemagglutinin-neuraminidase Hepatoma T Cell Anti-tumor immunity
  • 相关文献

参考文献12

  • 1Lech P. J., Russell S. J., Expert. Rev. Vaccines, 2010, 9(11), 1275.
  • 2Fournier P., Aigner M., Schirrmacher V., Int. J. Oncol., 2010, 37(5), 1203.
  • 3Scheid A., Choppin P. W., J. Virol., 1973, 11(2), 263.
  • 4Liu C., Air G. M., Virology, 1993, 194(1), 403.
  • 5Li X., Jin N., Lian H., Guan G., Sun L., Li X., Zheng H., Chinese Sci. Bull., 2006, 51(22), 2724.
  • 6Jin K., Jin N., Wang X., Ding Z., Guo Z., Wang H., Chang G., Yin Z., Chin. J. Prey. Vet. Med., 2000, 22(2), 143.
  • 7Chen L., Jin N., Li X., Liu L., Jia P., Liu Y., Gao P., Lu Y., Li M., Chi B., Chin. J. Immunol., 2009, 24(2), 132.
  • 8Li X., Liu Y., Wen Z., Li C., Lu H., Tian M., Jin K., Sun L., Gao P., Yang E., Xu X., Kan S., Wang Z., Wang Y., Jin N., Mol. Cancer, 2010, 20(9), 10.
  • 9Glogarova K., Buckiova D., Birth. Defects. Res. A. Clin. Mol. Teratol, 2004, 70(3), 142.
  • 10Guan G., Jin N., Mi Z., Li X., Lien H., Jin C., Sun L., Wen L., Chinese Journal of Otorhinolaryngology Head and Neck Surgery, 2005, 40(8), 566.

同被引文献16

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部